SCHEMBL10100664

SCHEMBL10100664

CC(C)CCn1cc(-c2cnc(N)c(-c3nnnn3-c3ccc(OCCC4CCNC4)c(F)c3F)c2)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 7/20 0.37
JAK2 O60674 9/20 0.34
JAK3 P52333 5/20 0.34
JAK1 P23458 4/20 0.34
TYK2 P29597 4/20 0.34
ALK Q9UM73 4/20 0.33
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
CTSS P25774 1/20 0.32
FGFR3 P22607 3/20 0.32
MAP4K3 Q8IVH8 3/20 0.32
FGFR1 P11362 2/20 0.32
PLK4 O00444 2/20 0.32
AURKA O14965 2/20 0.32
DCLK1 O15075 2/20 0.32
PRKD3 O94806 2/20 0.32
ABL1 P00519 2/20 0.32
NTRK1 P04629 2/20 0.32
INSR P06213 2/20 0.32
LCK P06239 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10100803 0.91 JAK2 (0.35) METJAK2PRMT5WDR77NTRK1
SCHEMBL10100628 0.91 MAP4K3 (0.39) METJAK2JAK3JAK1TYK2
SCHEMBL10100663 0.91 IRAK4 (0.37) METJAK2JAK3JAK1TYK2
SCHEMBL10100674 0.88 PRPS1 (0.34) METJAK2JAK3JAK1TYK2
SCHEMBL10100618 0.86 MAP4K3 (0.36) METJAK2JAK3JAK1TYK2
SCHEMBL10100609 0.86 MAP4K3 (0.36) METJAK2JAK3JAK1TYK2
SCHEMBL10100703 0.85 JAK2 (0.38) METJAK2PRMT5WDR77NTRK1
SCHEMBL2360138 0.85 JAK2 (0.38) METJAK2PRMT5WDR77NTRK1
SCHEMBL10100392 0.85 JAK2 (0.38) METJAK2PRMT5WDR77FGFR3
SCHEMBL10100800 0.85 KCNN4 (0.39) METJAK2PRMT5WDR77MAP4K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518938-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-27 US disclosed
US-8518938-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-27 US disclosed
US-20120165333-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
WO-2010048131-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165333-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 MET 1/4885JAK2 59/4885JAK3 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.